Adjuvant chemotherapy for colon cancer - Analysis of treatment costs from the perspective of statutory sickness funds

Zeitschrift fur Gastroenterologie

Volumn 46, Issue 7, 2008, Pages 681-688

  Gorner M ^a   Riemer Hommel, P ^b  

^a University Hospital of Bielefeld   (Germany)

^b Saarland University of Applied Sciences   (Germany)

Author keywords

Colon cancer; Cost evaluation; Inpatient chemotherapy; Outpatient chemotherapy

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADJUVANT THERAPY; ARTICLE; CANCER STAGING; COLON CANCER; CONTINUOUS INFUSION; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; GERMANY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEALTH SERVICE; HOSPITAL PATIENT; MULTIPLE CYCLE TREATMENT; OUTPATIENT DEPARTMENT; TREATMENT DURATION;

EID: 50149109387     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1027219     Document Type: Article

References (24)

1. Van Cutsem E, Dicato M, Wils J et al. Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). Eur J Cancer 2002; 38: 1429-1436
2. Obrand DI, Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum 1997; 40: 15-24
3. Obrand DI, Gordon PH. Continued change in the distribution of colorectal carcinoma. Br J Surg 1998; 85: 246-248
4. Petrelli N, Douglass Jr HO, Herrera L et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989; 7: 1419-1426
5. Poon MA, O'Connell MJ, Wieand HS et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991; 9: 1967-1972
6. Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351
7. Schmiegel W, Pox C, Adler G et al. S3-Leitlinienkonferenz "Kolorektales Karzinom" 2004. Z Gastroenterol 2004; 10: 1129-1177
8. InEK. Deutsche Kodierrichtlinien Version 2007. www.g-drg.de: 1-180
9. Gutachten des Sachverständigenrates für die konzertierte Aktion im Gesundheitswesen: Bedarfsgerechtigkeit und Wirtschaftlichkeit. Kohlhammer Verlag, Stuttgart
10. Grothey A, Kleeberg UR, Stauch M et al. Health economic analysis of fluoropyrimidine-based therapies of colorectal cancer from the perspective of statutory sickness funds. Z Gastroenterol 2005; 43: 155-161
11. Hieke K, Kleeberg UR, Stauch M et al. Costs of treatment of colorectal cancer in different settings in Germany. Eur J Health Econ 2004; 5: 270-273
12. Wolmark N, Rockette H, Mamounas E et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999; 17: 3553-3559
13. Andre T, Colin P, Louvet C et al. Randomized adjuvant study comparing two schemes of 5-fluorouracil and leucovorin in stage B 2 and C colon adenocarcinoma: study design and preliminary safety results. Groupe d'Etude et de Recherche Clinique en Oncologie Radiotherapies. Semin Oncol 2001; 28: 35-40
14. Twelves CJ. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness. Clin Colorectal Cancer 2006; 6: 278-287
15. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696-2704
16. Cassidy J, Douillard JY, Twelves C et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer 2006; 94: 1122-1129
17. Twelves C, Boyer M, Findlay M et al. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 2001; 37: 597-604
18. Chau I, Norman AR, Cunningham D et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 2005; 16: 549-557
19. Andre T, Tournigand C, Achille E et al. Adjuvant treatment of colon cancer MOSAIC study's main results. Bull Cancer 2006; 93 (Suppl 1): S5-S9
20. De Gramont A, Boni C, Navarro M et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007; 25: 4007
21. Jocham HR. Quality of life in palliative care - a comparison of hospital and home care. Pflege Z 2006; 59 (Suppl): 2-8
22. Wardley A, Davidson N, Barrett-Lee P et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 2005; 92: 1869-1876
23. Schmoll HJ, Cartwright T, Tabernero J et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 2007; 25: 102-109
24. de Gramont A, Tournigand C, Andre T et al. Targeted agents for adjuvant therapy of colon cancer. Semin Oncol 2006; 33: S42-S45